Personalized Cell Therapy Combined with Ibrutinib Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients
Perelman School of Medicine at the University of PennsylvaniaCombining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Cancer Center (ACC). The team will present the results from its pilot study of this combination therapy during the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract # 193355).